FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of immunology. Claimed is a version of Fc polypeptide of human IgG with substitutions 2591 and 308F, where numeration of positions is given in accordance with EU Kabat index. Described is a version of the said polypeptide, including one or several substitutions of the following: 428L, 434S, 307Q, 319L, 250I in addition to the said ones. Disclosed are: a nucleic acid, coding the said versions, a host cell for production of the said versions of polypeptide, which contains the coding nucleic acid, a method of obtaining the said versions of polypeptide, including application of the cell expressing the said polypeptide and containing the nucleic acid, which codes the said polypeptide.
EFFECT: application of the invention provides polypeptide, demonstrating higher affinity with human FcRn, which can be applied in therapy of different diseases.
11 cl, 32 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Fc VERSIONS WITH MODIFIED BINDING WITH FcRn | 2008 |
|
RU2529951C2 |
| VARIANTS OF Fc WITH CHANGED BINDING WITH FcRn | 2014 |
|
RU2700882C2 |
| Fc-VERSIONS WITH CHANGED BINDING WITH FcRn | 2005 |
|
RU2412200C2 |
| DESIGNED IL-2-FC FUSION PROTEINS | 2018 |
|
RU2812283C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| GENETICALLY ENGINEERED POLYPEPTIDES AND USE THEREOF | 2017 |
|
RU2822498C2 |
| POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
| NON-HUMAN ANIMALS EXPRESSING PH-SENSITIVE IMMUNOGLOBULIN SEQUENCES | 2013 |
|
RU2664473C2 |
| READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT | 2010 |
|
RU2522002C2 |
